Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Treatment of primary progressive multiple sclerosis.
Combined sequence-based and genetic mapping analysis of complex traits in outbred rats.
The axes of access--improving care for patients with disabilities.
An analytical model for estimating water exchange rate in white matter using diffusion MRI.
Genetic control of nerve conduction velocity may influence multiple sclerosis phenotype.
Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases.
Mechanics in Neuronal Development and Repair.
Critical role for PDE4 subfamilies in the development of experimental autoimmune encephalomyelitis.
Active Biotech's partner Teva initiates a laquinimod clinical trial in Huntington's disease
Treatment of Acute Disseminated Encephalomyelitis.
Anthraquinone derivative O,O'-bis-(3'-iodopropyl)-1,4-dihidroxyanthraquinone modulates immune response and improves experimental autoimmune encephalomyelitis.
Trigger, pathogen, or bystander: the complex nexus linking Epstein- Barr virus and multiple sclerosis.
Differential Cerebellar Functional Interactions during an Interference Task across Multiple Sclerosis Phenotypes.
Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex.
Atomic view of a toxic amyloid small oligomer.
The mechanism of action of interferon-β in relapsing multiple sclerosis.
How can we exploit the brain's ability to repair itself?
Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.
PML in MS Patients Making Natalizumab-to-Fingolimod Switch
Comparative study on the therapeutic potential of neurally differentiated stem cells in a mouse model of multiple sclerosis.
Strength-duration time constant in peripheral nerve: no abnormality in multiple sclerosis.
CC3-03: Drug Characteristics Associated with Medication Adherence Across Eight Disease States.
UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production.
Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature.
Association Between the Neurogenic Bladder Symptom Score and Urodynamic Examination in Multiple Sclerosis Patients With Lower Urinary Tract Dysfunction.
Pages
« first
‹ previous
…
261
262
263
264
265
266
267
268
269
…
next ›
last »